Indication
Ovarian
9 clinical trials
16 products
Clinical trial
A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Olaparib (PARP Inhibitor) in Patients With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2021-09-17
Product
OlaparibProduct
MEDI4736Product
BevacizumabProduct
Trastuzumab deruxtecanClinical trial
A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)Status: Active (not recruiting), Estimated PCD: 2023-06-08
Product
olaparibProduct
ChemotherapyClinical trial
Use of a Fasting Mimicking Diet in Patients Undergoing Chemotherapy for Gynecologic MalignanciesStatus: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Phase II, Open Label, Non Randomised, Non Comparative, Multicentre Study to Assess the Efficacy and Safety of Olaparib Given Orally Twice Daily in Patients With Advanced Cancers Who Have a Confirmed Genetic BRCA 1 and/or BRCA2 MutationStatus: Active (not recruiting), Estimated PCD: 2012-07-31
Product
NiraparibClinical trial
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2024-03-29
Product
Standard of careProduct
Dostarlimab-PlaceboProduct
Niraparib-PlaceboProduct
DostarlimabClinical trial
An Exploratory Comparative Effectiveness Analysis of Granulocyte Colony Stimulating Factor Originator Products Versus Biosimilars in Real-world PracticeStatus: Completed, Estimated PCD: 2022-09-30
Clinical trial
A PHASE 1-2 NEOADJUVANT DOSE FINDING, SAFETY, AND IMMUNOLOGIC EFFICACY TRIAL OF INTENSIVE LOCOREGIONAL CHEMOIMMUNOTHERAPY FOR RECURRENT OVARIAN CANCER AND TUMOR-SPECIFIC INTRANODAL AUTOLOGOUS ALPHA-DC1 VACCINESStatus: , Estimated PCD: 2025-12-31
Clinical trial
A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Expansion Study of AVB-001, an Intraperitoneally Administered, Cell-Generated, Human IL-2 Immunotherapy in Patients With Platinum-Resistant, High-Grade, Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian TubeStatus: Terminated, Estimated PCD: 2024-04-01
Product
AVB-001Clinical trial
Phase Ia/Ib Open Label, Multi-Centre Dose Escalation Study With Expansion Cohorts to Assess the Safety, Tolerability, and Activity of DSB2455 as Monotherapy or in Combination With Anti-Cancer Agents in Participants With Advanced MalignanciesStatus: Not yet recruiting, Estimated PCD: 2027-08-01
Product
DSB2455